Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
Autolus Therapeutics plc, a US-listed commercial stage biopharmaceutical company specializing in next-generation programmed T cell therapies, will release its Q1 2026 financial results on May 14, 2026, before US market open. The company will also host a conference call and webcast to discuss financial outcomes and provide a business update.